VALIANT: Pegcetacoplan for C3G or primary (idiopathic) IC-MPGN

• ISPOR-Eu •
• 8 November, 2026 •
• •

Kidney Transplant Reallocation: Quantifying Cost Savings and QALY Gains from Disease-Modifying Treatments for the UK NHS

Zalmai Hakimi, Carly Rich, Michal Górecki, Jameel Nazir, Michał Pochopień

• ESPN •
• 2 October, 2026 •
• •

Pegcetacoplan treatment response in VALIANT/VALE: Impact of genetic and acquired complement dysregulation and disease type in C3 glomerulopathy and primary (idiopathic) immune complex membranoproliferative glomerulonephritis

Nicole Van De Kar, Marina Norris, Daniel P Gale, Sophie Chauvet, Fernando Caravaca-Fontán, Julia Weinmann-Menke, Bradley P Dixon, Carla M Nester, Lucía Quintana-Gallardo, Johan Szamosi, Kathryn Gordon, Anwesha Mukherjee, Fadi Fakhouri

Available materials

• ESPN •
• 2 October, 2026 •
• •

Real-world effectiveness and safety of pegcetacoplan in patients with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis: PRISM-C3, a multi-country Phase 4 study

David Kavanagh, Matthew C Pickering, Terence Cook, Marina Vivarelli, Moglie Le Quintrec, Véronique Frémeaux-Bacchi, Virginia Taliadouros, Elena Surova, Nicholas Webb, Fadi Fakhouri

Available materials

• ESPN •
• 2 October, 2026 •
• •

Pegcetacoplan sustained clinical benefit in adolescent patients with C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis through 1 year of therapy: Data from VALIANT/VALE

Christoph Licht, Gema Ariceta, Yael Borovitz, Bradley P Dixon, Naoya Fujita, Antonio Mastrangelo, Nabil Melhem, Nicole Van De Kar, Marina Vivarelli, Dean Wallace, Virginia Taliadouros, Johan Szamosi, Kathryn Gordon, Zhongshen Wang, Carla M Nester

Available materials